Detailed explanation of the second-generation EGFR targeting drug dacomitinib (dacomitinib) and its clinical application

Dacomitinib (Dacomitinib), as a second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI), has demonstrated its unique value in the treatment of non-small cell lung cancer (NSCLC). EGFR is an important therapeutic target, especially in NSCLC patients, the proportion of gene mutations is about 15%-20%, which makes targeted therapy against EGFR of great significance in clinical application.

Early first-generation EGFR-TKI drugs, such as gefitinib (Gefitinib) and erlotinib (Erlotinib), have achieved significant efficacy in inhibiting EGFR activity and effectively prolonged the survival of patients. However, drug resistance issues, especially those caused by the EGFR T790M mutation, limit the long-term effectiveness of these drugs. To overcome this challenge, scientists have further developed second- and third-generation EGFR-TKIs.

Dacomitinib , as a representative of the second generationEGFR-TKI, shows stronger inhibitory activity than the first generation drugs. By irreversibly binding to EGFR tyrosine kinase, it broadly inhibits various EGFR mutations, including common L858R and Exon 19 deletion mutations. Clinical trial data show that dacomitinib (dacomitinib) has better efficacy than the first-generation EGFR-TKI in delaying disease progression and improving patient survival.

In 2018, based on the positive results of the ARCHER 1050 clinical trial, the U.S. Food and Drug Administration (FDA) approved dacomitinib for the treatment of patients with metastatic non-small cell lung cancer who have EGFR mutations. The trial showed that dacomitinib (dacomitinib) significantly prolonged progression-free survival (PFS) and overall survival (OS) compared with gefitinib. However, it is worth noting that the use of dacomitinib is also associated with a higher risk of adverse reactions, such as rash, diarrhea, and stomatitis, which requires clinicians to conduct close monitoring and management during use.

Althoughdacomitinib has shown significant efficacy in the treatment of EGFRmutated NSCLC With the emergence of third-generation EGFR-TKIs such as Osimertinib (Osimertinib), treatment strategies are also constantly developing and improving. The third generation EGFR-TKIhas a significant effect against T790M resistance mutation, while also improving in terms of safety and tolerability. Therefore, in actual clinical practice, doctors will select the most suitable EGFR-TKI for targeted therapy based on the patient's specific gene mutation type and drug resistance.